- FDA labeling updated in March 2026 covers a rare genetic folate transport disorder, not autism.
- Evidence for leucovorin in autism comes from small trials; large studies are lacking.
- Prescriptions for autistic children rose more than 24-fold by November 2025, a 2026 study found.
- Health claims can spread far faster than the evidence behind them.
*Update, November 2, 2026: in January 2026 the European Journal of Pediatrics retracted what The Transmitter called the largest trial of leucovorin in autistic children. For the current label, the retraction and insurance coverage, read our plain-English leucovorin update for parents.*
When political figures make health claims about autism, families listen. That is not a flaw in families. It is a flaw in the information environment.
On September 22, 2025, President Trump and HHS Secretary Robert F. Kennedy Jr. promoted leucovorin as a treatment for speech-related difficulties associated with autism. Leucovorin, also called folinic acid, is a form of folic acid. Its FDA-approved uses include reducing the toxicity of the cancer drug methotrexate.
In March 2026, updated FDA-approved labeling for leucovorin tablets, such as the Wellcovorin label on DailyMed, added a new indication: treating cerebral folate transport deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD). That is a rare genetic condition. Autism is not a labeled indication.
That distinction matters.
What the Research Actually Shows
As researchers writing in JAMA Network Open summarized, some evidence from small clinical trials has suggested that folate-deficient children treated with leucovorin may show improved verbal communication, but large-scale studies confirming its safety and efficacy are lacking.
A rare genetic folate transport disorder is a distinct condition. Conflating a treatment for a specific, genetically confirmed condition with a treatment for autism itself is not a minor error.
The Real Harm: Documented
What makes this story more than a policy dispute is what came next. A 2026 study in JAMA Network Open, using electronic health records from more than 838,000 children with autism, found that leucovorin prescription rates had been stable for two years, began a steadier rise in February 2025 around the time a national news segment featured the drug, and then rose sharply after the September 2025 announcement. By November 2025, the rate was more than 24 times the 2023 to 2025 monthly average.
Families and clinicians changed their behavior before large studies had confirmed safety and effectiveness for autism. That is the concrete cost of health claims running ahead of the evidence.
Why WeBearish Tracks This
WeBearish is not a medical authority and does not give medical advice. What we do is make sure families have access to accurate information about where the science actually stands.
The pattern here is one the autism community has seen before: a promising early signal, amplification, and widespread uptake before the evidence is in.
Families deserve better than that.
The Acceptance Framework Holds
None of this changes the fundamental WeBearish position. Autism is not a disease requiring pharmaceutical correction. The children these treatments are aimed at are not broken. The goal of any intervention should be improving quality of life and wellbeing for the autistic person, not making them appear less autistic.
Legitimate science, when it produces real tools that help autistic people on their own terms, is worth knowing about. Political claims dressed as science, running ahead of the evidence, cause harm. The distinction is always worth making.
---
Sources
- Wellcovorin (leucovorin calcium) FDA label, DailyMed, indications updated March 2026 - Rothman JM, Kwan B, Longhurst CA, Jena AB. Rates of Leucovorin Prescriptions for Children With Autism. JAMA Network Open, 2026
More from WeBearish
- The Neurodiversity Movement, Where it came from and where it is going - Autism Awareness vs. Acceptance, What the difference looks like in practice - Join the WeBearish Community, No tragedy narratives.
Frequently Asked Questions
Did the FDA approve leucovorin as a treatment for autism?
No. Updated FDA-approved labeling in March 2026 added treatment of cerebral folate transport deficiency in people with a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD), a rare genetic condition. Autism is not a labeled indication, even though the White House promoted leucovorin for autism in September 2025.
What does the research on leucovorin and autism actually show?
As researchers writing in JAMA Network Open in 2026 summarized, some evidence from small clinical trials suggests folate-deficient children treated with leucovorin may show improved verbal communication, but large-scale studies confirming its safety and efficacy are lacking. A genetic folate transport disorder is a distinct condition from autism itself.
What real-world harm came from the political claims about leucovorin?
A 2026 study in JAMA Network Open, using health records from more than 838,000 children with autism, found leucovorin prescription rates rose sharply after the September 2025 announcement, reaching more than 24 times the 2023 to 2025 monthly average by November 2025. Clinicians and families changed their behavior before large studies had confirmed safety and effectiveness for autism.